Category: Oncotarget

Oncotarget News

Oncotarget Editorial Highlights Advances in Scientific Integrity and Publishing Transparency

April 10, 2026

Scientific integrity is a crucial component of scholarly publishing.”BUFFALO, NY - April 10, 2026 – A new editorial perspective was published in Volume 17 of Oncotarget on... read more

Oncotarget

Adjuvant PD-1/PD-L1 Inhibitors Show Efficacy but Highlight Safety Considerations in Solid Cancers

April 7, 2026

Programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors are widely used in cancer treatment.”BUFFALO, NY - April 7, 2026 – A new research paper was published in Volume... read more

Oncotarget

Bibliometric Mapping Reveals the Evolution of Glioma Classification Research

April 6, 2026

The findings indicate that the subset of articles focusing on glioma classification that incorporate social factors is relatively scarce in the analyzed data, in contrast to the prominence of epigenetic... read more

Oncotarget

The SCD1 Inhibitor Aramchol, Regorafenib, and Metformin Combine to Kill Uveal Melanoma Cells

March 31, 2026

Aramchol and metformin interacted to modestly enhance cell death in PDX UM cells, though this was less than that caused by the combination of aramchol and the multi-kinase inhibitor regorafenib.”... read more

Oncotarget

CREB5 Linked to Stem Cell-Like Programs That Promote Prostate Cancer Progression

March 24, 2026

We determined that CREB5 is a key regulator of basal and SCL transcriptional programs and tumor-forming phenotypes in PC.”BUFFALO, NY - March 24, 2026 – A new research paper was published... read more

Oncotarget

Impact Journals to Participate at AACR Annual Meeting 2026 in San Diego

March 16, 2026

Conference attendees are warmly invited to visit Booth 3641 to meet members of the Impact Journals team, discover notable recent publications, and discuss opportunities for collaboration.BUFFALO, NY – March 16,... read more

Oncotarget

Next-Generation CAR-T Designs That Could Transform Cancer Treatment

February 25, 2026

CAR T-cell therapy has emerged as a particularly promising cancer-specific treatment strategy.”BUFFALO, NY - February 25, 2026 – A new editorial perspective was published in Volume 17 of Oncotarget on February... read more